MilliporeSigma
  • Home
  • Search Results
  • Sorafenib and everolimus in advanced clear cell renal carcinoma: a phase I/II trial of the SCRI Oncology Research Consortium.

Sorafenib and everolimus in advanced clear cell renal carcinoma: a phase I/II trial of the SCRI Oncology Research Consortium.

Cancer investigation (2013-04-26)
John D Hainsworth, David M Waterhouse, William C Penley, Dianna L Shipley, Dana S Thompson, Charles D Webb, F Anthony Greco
ABSTRACT

To evaluate the feasibility and efficacy of sorafenib and everolimus in renal cell carcinoma (RCC). Patients with advanced RCC and ≤ 1 previous targeted therapy were treated. Maximum tolerated doses were sorafenib 200 mg PO BID, everolimus 35 mg PO once weekly. Dose-limiting toxicity was hand-foot syndrome. The response rate was 13%; median PFS was 5.45 months (95% CI: 3.8-7.6). Skin toxicity, fatigue, hypertension, proteinuria, and mucositis (usually Grade 2) were common. Fifty percent doses of sorafenib and everolimus were required when these drugs were combined. No increase in efficacy was suggested; toxicity was modestly increased.

MATERIALS
Product Number
Brand
Product Description

Supelco
Nicotinamide (Niacinamide), analytical standard
Supelco
Niacinamide, Pharmaceutical Secondary Standard; Certified Reference Material
Sigma-Aldrich
Niacinamide, meets USP testing specifications
Sigma-Aldrich
Nicotinamide, ≥98% (HPLC), powder
Sigma-Aldrich
Nicotinamide, BioReagent, suitable for cell culture, suitable for insect cell culture
Sigma-Aldrich
Nicotinamide, ≥99.5% (HPLC)
Sigma-Aldrich
Nicotinamide, ≥98.5% (HPLC)
Nicotinamide, European Pharmacopoeia (EP) Reference Standard
Supelco
Nicotinamide (Vitamin B3) solution, 1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®